A six-year study that analyzed data from a 25-question screening tool found alarming evidence of unhealthy behavioral trajectories starting as early as age 2 among families affected by low income and other social stressors.
Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor
AstraZeneca and Daiichi Sankyo are changing the approval submission strategy for its planned Enhertu successor, datopotamab deruxtecan (Dato-DXd), after a few missed trials. The companies
November 13, 2024